POLE3
POLE3 (DNA polymerase epsilon subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
Overview
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication. Forms a complex with CHRAC1 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome-remodeling activity of ISWI/SNF2H and ACF1.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.14, genetic association 0.03, clinical 0.99).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · POLE3 (DNA polymerase epsilon subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
- 1 · What it is
POLE3 (DNA polymerase epsilon subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
- 2 · What goes wrong in cancer
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication.
- 3 · How drugs use it
No product in this corpus aims at POLE3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:13546 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NRF9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000148229 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.59, ovarian cancer 0.58, acute myeloid leukaemia 0.59, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.60 (GraphQL API, CC0))
Biology
Accessory component of the DNA polymerase epsilon complex. Participates in DNA repair and in chromosomal DNA replication. Forms a complex with CHRAC1 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome-remodeling activity of ISWI/SNF2H and ACF1. Does not enhance nucleosome sliding activity of the ACF-5 ISWI chromatin remodeling complex. Location: Nucleus (UniProt). Locus 9q32 (HGNC).
- Leukaemia: Open Targets association 0.60 with leukaemia (MONDO_0005059)
- Non-Hodgkin lymphoma: Open Targets association 0.60 with non-Hodgkin lymphoma (MONDO_0018908)
- Lung cancer: Open Targets association 0.59 with lung cancer (MONDO_0008903)
- Myeloproliferative neoplasms: Open Targets association 0.59 with myeloproliferative neoplasm (MONDO_0020076)
- Breast cancer: Open Targets association 0.58 with breast cancer (MONDO_0007254)
- Ovarian cancer: Open Targets association 0.58 with ovarian cancer (MONDO_0008170)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"POLE3" OR ABSTRACT:"POLE3" OR TITLE:"DNA polymerase epsilon 3, accessory subunit" OR ABSTRACT:"DNA polymerase epsilon 3, accessory subunit" OR TITLE:"DNA polymerase epsilon subunit 3" OR ABSTRACT:"DNA polymerase epsilon subunit 3" OR TITLE:"CHRAC17" OR ABSTRACT:"CHRAC17" OR TITLE:"Ybl1" OR ABSTRACT:"Ybl1" OR TITLE:"p17" OR ABSTRACT:"p17") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLE3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPOLA2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD3
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLD4
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPOLE2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPRIM1
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetPRIM2
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).
- TargetRRM2B
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types).